Fulcrum's sickle cell disease program is back in business after FDA lifts 6-month hold

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 22, 2023 at 10:12: AM
via After a six-month wait, Fulcrum Therapeutics’ sickle cell disease (SCD) plans are back on track after the FDA lifted a hold on the biotech’s candidate.

article source
 

<



Similar threads

cafead
FDA placed hold on Fulcrum&#039;s sickle cell therapy over hematological malignancy concerns
Replies
0
Views
215
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Fulcrum&#039;s clinical hold caps off tough week for sickle cell drug development
Replies
0
Views
215
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Aiming to brush last year&#039;s flop aside, Fulcrum sees shares skyrocket on early look at...
Replies
0
Views
86
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Fulcrum stock slumps after muscle disorder drug fails in late-stage study
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline
Replies
0
Views
58
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote